5-Amino-1MQ

5-Amino-1MQ is an experimental small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) studied in cellular and animal models of metabolism. Although it is sometimes promoted online as a “fat burner,” scientific research primarily examines NNMT signalling, NAD⁺ metabolism and adipose-tissue biology. It is not an approved treatment for human weight loss.

Unlike GLP-1-based medicines such as tirzepatide or the investigational compound retatrutide, 5-Amino-1MQ is not designed to suppress appetite. It targets the enzyme NNMT, which participates in energy metabolism and has been reported to show greater activity in adipose tissue from people with obesity than in tissue from leaner individuals. This has led researchers to ask whether NNMT inhibition could alter how efficiently cells use energy.

Why might this matter? In simplified terms, NNMT activity can influence levels of NAD⁺, a molecule central to cellular energy production. Some experimental studies suggest that inhibiting NNMT may raise cellular NAD⁺ concentrations, which could theoretically affect energy use and lipid storage. These proposed mechanisms remain research questions rather than established human outcomes.

A study published in 2017 evaluated 5-Amino-1MQ in an obese-mouse model. During the short experimental period, researchers reported changes in body mass, adipose tissue and metabolic markers. These are animal-model findings and cannot be converted directly into predictions about human weight loss, effectiveness or safety.

Laboratory studies have also reported reduced formation of new fat cells and lower lipid accumulation within them. In other words, the compound may influence experimental pathways involved not only in existing fat stores but also in future fat-cell development. This has made it a notable NNMT inhibitor in metabolic research.

Researchers have also begun examining other potential areas related to NNMT inhibition. Preclinical work has explored associations with muscle function during ageing, inflammatory signalling and broader metabolic changes. Most evidence in these areas still comes from laboratory or animal studies.

5-Amino-1MQ has shown selectivity for NNMT in preclinical experiments, but selectivity in a laboratory model does not establish safety in humans. Controlled clinical studies are insufficient to determine effectiveness, adverse effects or long-term risk. The compound therefore remains a metabolic-research tool rather than an approved weight-loss intervention.